drugset / Trial / NCT06961968

Randomized Withdrawal Study in Patients With Schizophrenia

NCT06961968

Phase 3 Recruiting 400 enrolled Vanda Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in patients with schizophrenia.

Timeline

Start
2025-05-14
Primary completion
2027-11
Completion
2027-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Iloperidone Small molecule Oral

Indications